| Literature DB >> 33278135 |
Matthijs In 't Veld1, Engelbert A J M Schulten, Frank K J Leusink.
Abstract
PURPOSE OF REVIEW: Oral rehabilitation with dental implants in head and neck cancer (HNC) patients is challenging. After tooth removal prior to radiotherapy, immediate placement of dental implants during panendoscopy or surgery is thought to reduce the oral rehabilitation time improving patients' quality of life. RECENTEntities:
Mesh:
Substances:
Year: 2021 PMID: 33278135 PMCID: PMC7969163 DOI: 10.1097/MOO.0000000000000685
Source DB: PubMed Journal: Curr Opin Otolaryngol Head Neck Surg ISSN: 1068-9508 Impact factor: 1.814
FIGURE 1Flowchart of article selection process.
Characteristics of the 10 included studies in the literature review
| Ref. | Study type | Groups | No. of patients | Sex (M/F) | Age range (years) | Radiotherapy (None, pre, post) | Radiation dose (Gray) | Implant system | Implant type | Timing of implant placement (immediate, postponed or both) | Osseointegration period for abutment connection in months | Follow-up range (months) |
| Ettl | Prospective | RTX vs. non-RTX | 52 | 38/14 | 48–82 | None and post | 40–72 | Astra Tech | Osseospeed (ASTRA TECH Implant System, Molndal, Sweden) | Immediate | 4–6 | 12 max. |
| Korfage | Prospective | RTX vs. non-RTX | 50 | 35/15 | 41–81 | None and post | > 40 | NobelBiocare (Brånemark) | 3.75 mm Brånemark screw implants with a machined surface (Nobel BioCare, Gothenburg, Sweden) | Immediate | 3 or 9 | 60 max. |
| Korfage | Prospective | RTX vs. non-RTX | 164 | 98/66 | 39–88 | Post | Unknown | NobelBiocare (Brånemark) | 3.75 mm Brånemark implants (Nobel BioCare, Gothenburg, Sweden), with a machined surface or a Ti-Unite surface | Immediate | 3 or 9 | 174 (median 45.6) |
| Mizbah | Retrospective | DAS vs. P | 510 | 294/216 | Unknown | Post | > 60 | NobelBiocare (Brånemark) | Brånemark Mk II/III two-phase implants or Frialit two-phase implants | Both | 3 or 9 | 60 max. |
| Schepers | Retrospective | RTX vs. non-RTX | 48 | 29/19 | 64.8 mean | None and post | > 60 | NobelBiocare (Brånemark) | Brånemark Mk II/III two-phase implants | Immediate | Minimal 3 | 89 max. |
| Schoen | Prospective | RTX | 5 | 3/2 | 48–69 | Post | > 60 | NobelBiocare (Brånemark) | Brånemark implants (Nobel BioCare, Gothenburg, Sweden) | Immediate | Minimal 3 | 13–40 |
| Schoen | Prospective | RTX vs. non-RTX | 50 | 35/15 | 41–81 | None and post | > 30 | NobelBiocare (Brånemark) | Brånemark implants (Nobel BioCare, Gothenburg, Sweden) | Immediate | 3 or 9 | 24 max. |
| Wetzels | Prospective | DAS vs. P | 56 | 33/23 | 69.6 mean | None and post | 56–66 | NobelBiocare (Brånemark) | Brånemark Mk III two-phase implants; Nobel BioCare, Gothenburg, Sweden. | Both | 3 or 9 | 60 max. |
| Wetzels | Retrospective | DAS vs. P | 193 | 104/89 | 67.3 mean | None and post | < 70 | NobelBiocare (Brånemark) or Straumann or Astra Tech | Brånemark Mk III two-phase implants (Nobelbiocare, Gothenburg, Sweden), Straumann (Basel, Switzerland) or Osseospeed (ASTRA TECH Implant System, Molndal, Sweden) | Both | 3 or 9 | 60 max. |
| Woods | Retrospective | DAS vs. P | 20 | 13/7 | 17–91 | None and post | – | Straumann or Neoss | ITI/Straumann (Basel, Switzerland) or Neoss implant (Neoss, Harrogate, UK) | Both | – | 2–140 |
DAS, during ablative surgery; Gy, Gray; n-RTX, nonradiotherapy; P, postponed; RTX, radiotherapy.
Tumour characteristics of the 10 included studies in the literature review
| Ref. | Primary tumour | No. of patients | Tumour (T) | No. of patients (%) | Lymph nodes ( | No of patients (%) |
| Ettl | Anterior FOM, tongue or mandible | 12 (43%) | T1 | 7 (25%) | N0 | 18 (62%) |
| Lateral FOM, BOT, DM, OP | 15 (52%) | T2 | 11 (39%) | N1 | 2 (7%) | |
| Larynx, hypopharynx | 2 (7%) | T3 | 4 (14%) | N2 | 9 (31%) | |
| T4 | 6 (21%) | |||||
| Korfage | FOM, tongue | 29 (58%) | T1 | 6 (12%) | N0 | 28 (56%) |
| BOT, OP | 6 (12%) | T2 | 21 (42%) | N1 | 11 (22%) | |
| Mandibular gingiva | 12 (24%) | T3 | 10 (20%) | N2 | 11 (22%) | |
| Tonsil | 3 (6%) | T4 | 13 (26%) | |||
| Korfage | – | – | – | – | – | – |
| Mizbah | – | – | – | – | – | – |
| Schepers | FOM or tongue | 13 (62%) | ||||
| Buccal mucosa | 1 (5%) | |||||
| Retromolar trigone | 6 (28%) | |||||
| Lower alveolar ridge | 1 (5%) | |||||
| Schoen | FOM | 1 (20%) | T1 | 0 (0%) | N0 | 1 (20%) |
| BOT | 2 (40%) | T2 | 0 (0%) | N1 | 3 (60%) | |
| OP | 2 (40%) | T3 | 4 (80%) | N2 | 1 (20%) | |
| T4 | 1 (20%) | |||||
| Schoen | FOM, tongue | 29 (58%) | T1 | 6 (12%) | N0 | 28 (56%) |
| BOT, OP | 6 (12%) | T2 | 21 (42%) | N1 | 11 (22%) | |
| Mandibular gingiva | 12 (24%) | T3 | 10 (20%) | N2 | 11 (22%) | |
| Tonsil | 3 (6%) | T4 | 13 (26%) | |||
| Wetzels | FOM or tongue | 10 (42%) | T1 | 2 (8%) | ||
| Mandible | 11 (46%) | T2 | 12 (50%) | |||
| Maxilla | 2 (12) | T3 | 1 (4%) | |||
| T4 | 8 (38%) | |||||
| Wetzels | Tongue or FOM | 56 (57%) | T1 | 20 (21%) | N0 | 60 (61%) |
| Lower alveolar process | 24 (25%) | T2 | 43 (44%) | N1 | 11 (11%) | |
| Maxilla | 6 (6%) | T3 | 14 (14%) | N2 | 27 (28%) | |
| Lip | 4 (4%) | T4 | 21 (21%) | |||
| Cheek | 8 (8%) | |||||
| Woods | – | – | – | – | – | – |
BOT, base of tongue; DCIA, deep circumflex iliac artery flap; DM, dorsal maxilla; FFF, free fibular flap; FOM, floor of mouth; OP, oropharynx; OSCC, oral squamous cell carcinoma.
Placement during ablative surgery vs. postponed placement of dental implants: implant survival and complications, based on the 10 included studies in the literature review
| Ref. | No. of irradiated/nonirradiated patients | No. of irradiated/nonirradiated implants | No. of patients receiving implants immediately/ delayed | No. of implants immediate/delayed placement | Implant tissue (no. of implants) | Implant location (no. of implants) | Implant survival (survival rate) | Total implants lost (DAS/P) | No. of functional implants (%) | No. of functional overdentures (%) | Average time between operation and placement of overdenture | HBO2-therapy |
| Mizbah | 64/64 | 151/163 | 99/29 | 249/65 | NB | Mandible | 284 (90.4%) | 30 (24/6) | 205/249 (82.3%) in DAS-group 59/65 (90.8) in P-group | 82/99 (82.8%) in DAS-group 27/29 (93.1%) in P-group | 7.4 months (mean) in DAS-group 27.4 months (mean) in P-group | Yes |
| Wetzels | 34/22 | Unknown | 18/9 | 40/19 | NB (34 patients) Plate reconstruction (7 patients) Obturator (9 patients) FF or DCIA (6 patients) | Maxilla and mandible | Unknown | Unknown | 27/40 (67.5%) after 5 years in DAS group | 13 in DAS-group after 5 years 9 conventional dentures in P-group after 5 years | 325 days in DAS-group 396 days in P-group | Yes |
| Wetzels | Unknown | Unknown | 79/18 | 225/43 | NB (135 patients) Plate reconstruction (22 patients) Obturator (15 patients) FF or DCIA (21 patients) | Maxilla (44) and mandible (224) | 248 (92.5%) | 20 (17/3) | 173/225 (76.9%) in DAS-group after 5 years 37/43 (86.0%) in P-group after 5 years | 61/62 (98.4%) in DAS- group after 5 years 16/16 (100%) in P-group after 5 years | 291 days in DAS-group 389 days in P-group | Yes |
| Woods | 10/10 | 51/51 | Unknown | 39/63 | NB (92) + FF (10) | Maxilla and mandible | 95 (93.1%) | 7 (1/6) | 24/39 (61.5%) in DAS-group 56/63 (88.9%) in P-group | Unknown | 321 days in DAS-group 726 days in P-group | Yes |
DAS, placement during ablative surgery; DCIA, deep circumflex iliac artery flap; DM, dorsal maxilla; FFF, free fibular flap; GB, grafted bone; HBO2, hyperbaric oxygen therapy; MB, mandible; MX, maxilla; NB, native bone; P, postponed placement.
Forest plots displaying the results of the meta-analysis regarding implant loss
DAS, during ablative surgery; non-RTX, nonradiotherapy; P, postponed; RTX, radiotherapy.
Radiotherapy vs. nonradiotherapy: dental implant survival and functionality and complications, based on the 10 included studies in the literature review
| Ref. | No. of irradiated/nonirradiated patients | No. of irradiated/nonirradiated implants | No. of implants immediate/delayed placement | Implant tissue (no. of implants) | Implant location (no. of implants) | Implant survival (survival rate) | Total implants lost (RTX/non-RTX) | No. of functional implants immediately placed | No. of functional overdentures (RTX/non-RTX) | Average time between operation and placement of overdenture | HBO2-therapy |
| Ettl | 20/9 | 110/52 | 0/165 | NB (147) FF or DCIA (18) | Maxilla (57) + mandible (108) | 157 (95.2%) | 8 (unknown) | 143/165 | 29 (unknown) | Unknown | Unknown |
| Korfage | 31/19 | 133/62 | 195/0 | NB | Mandible | 181 (92.8%) | 14 (13/1) | 76 implants after 5 years | 20 after 5 years (9/11) | Unknown | Unknown |
| Korfage | 100/64 | 318/206 | 524/0 | NB | Mandible | 496 (94.6%) | 28 (27/1) | Unknown | 138 (81/57) | 11.3 months in RTX-group 6.2 months in n-RTX-group | Yes |
| Schepers | 21/27 | 61/78 | 139/0 | NB | Mandible | 137 (98.6%) | 2 (2/0) | 46/61 in RTX group 59/78 in non-RTX group | 36 (15/21) | Unknown | Unknown |
| Schoen | 4/0 | 16/0 | 16/0 | NB | Mandible | 16 (100.0%) | 0 (0/0) | 16/16 in RTX group | 4 (4/0) | Unknown | Unknown |
| Schoen | 31/19 | 124/76 | 200/0 | NB | Mandible | 196 (98.0%) | 4 (2/2) | 76 in RTX group with functional overdenture 64 in non-RTX group with functional overdenture | 35 (19/16) | Unknown | Unknown |
| Wetzels | 39/39 | 94/88 | 182/0 | NB | Mandible | 174 (95.5%) | 12 (8/4) | Unknown | Unknown | Unknown | Yes |
DAS, placement during ablative surgery; DCIA, deep circumflex iliac artery flap; DM, dorsal maxilla; FFF, free fibular flap; GB, grafted bone; HBO2, hyperbaric oxygen therapy; MB, mandible; MX, maxilla; NB, native bone; n-RTX, not receiving radiotherapy; RTX, receiving radiotherapy.